



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Erin Tower

Tel: (847) 491-4401

Fax: (847) 491-8510

erin@ohmx.com

Recent Ohmx publication featured in media

Evanston IL, September 16th 2013 – Ohmx Corporation, is pleased to announce their recent paper, “PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness,” has been featured in a number of articles since its publication in *The Prostate* on August 9th, 2013. The paper, which discusses a new biomarker suitable for assessing the aggressiveness of prostate cancer, has been featured in *Nature Reviews Urology* Research Highlights and *Chemical & Engineering News*, **C&EN Concentrates**. Their data and their presentation at the recent AACC meeting were also featured online by **MD Linx** and the **Advance Healthcare Network**.

Annette Fenner of *Nature Reviews Urology* wrote a Research Highlight article showcasing the findings of Ohmx’s paper and explaining the relevance of their study. Fenner’s article included comments from Ohmx’s Mike Ahrens, first author on the recently published paper. Ahrens told Fenner “We sought to develop a biomarker that could help close the knowledge gap and provide crucial information regarding the aggressiveness of disease and therefore reduce the number of unnecessary interventions.” The Research Highlight, entitled “Prostate cancer: PSA enzymatic activity to assess disease aggressiveness” was published online August 27th, 2013.

Stu Borman of C&EN wrote an article entitled “Antigen Levels Show Prostate Cancer’s Aggressiveness” for the Science and Technology Concentrates section of C&EN published on August 26th, 2013. Borman’s article provided an accurate and concise summary of the Ohmx paper to the C&EN community of readers.

When asked about the recent publication and coverage, Ohmx founder Thomas Meade commented: “It is quite impressive that Ohmx, which has established a proprietary platform for POC systems, has discovered a biomarker that will change the face of prostate cancer management.”

The original paper can be found in ***The Prostate***.

Articles

Prostate cancer: PSA enzymatic activity to assess disease aggressiveness. Fenner, A., *Nature Reviews Urology* 2013, DOI: 10.1038/nrurol.2013.187

Antigen Levels Show Prostate Cancer's Aggressiveness. Borman, S., *Chemical & Engineering News*, 91(34), 2013, pp. 24-25, <http://cen.acs.org/articles/91/i34/Antigen-Levels-Show-Prostate-Cancers.html>

Paper

PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness. M. J. Ahrens, P. A. Bertin, E. F. Vonesh, T. J. Meade, W. J. Catalona, D. G. Georganopoulou, *The Prostate* 2013, DOI: 10. 1002/pros.22714

About the Company:

Ohmx is a clinical diagnostic company that is developing a low-cost, bioelectronic, point-of-care (POC) reader that quantifies analytes from a low-volume biological sample (e.g. whole blood, urine, semen, prostatic fluid, etc). Ohmx's market entry strategy is based on a portable blood analyzer to assist clinicians with the diagnosis and monitoring of patients with chronic diseases in the physician office lab (POL) setting. The Ohmx POC device will enable doctors to quickly and cost-effectively diagnose, monitor and better manage patients with chronic diseases. The company's initial focus is on the diabetes market, with plans for cardiac markers and prostate cancer in the future.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.